Relay Therapeutics (NASDAQ:RLAY) CFO Sells $230,498.17 in Stock

Key Points

• CFO Thomas Catinazzo sold 17,717 shares on April 7 at an average price of $13.01 for $230,498.17 under a pre-arranged Rule 10b5-1 plan, trimming his holdings by 7.65% to 213,867 shares (≈$2.78M).
• Catinazzo also executed additional insider sales this year (1,800 shares at $15.00 on April 9 and earlier January disposals), indicating multiple planned stock liquidations.
• RLAY stock traded up 3.4% to $15.00 (a 12‑month high), the company has a ~$2.68B market cap, and analysts are mostly positive with several recent price‑target raises and an average target of $18.43.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 17,717 shares of the firm's stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $13.01, for a total transaction of $230,498.17. Following the completion of the transaction, the chief financial officer directly owned 213,867 shares in the company, valued at approximately $2,782,409.67. This represents a 7.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $27,000.00.
• On Wednesday, January 28th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The shares were sold at an average price of $8.45, for a total transaction of $14,322.75.
• On Tuesday, January 27th, Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40.

Relay Therapeutics Stock Up 3.4%

Shares of RLAY stock traded up $0.49 during mid-day trading on Thursday, reaching $15.00. The company's stock had a trading volume of 3,079,104 shares, compared to its average volume of 2,889,805. The company's 50 day simple moving average is $9.95 and its 200-day simple moving average is $8.11. Relay Therapeutics, Inc. has a 12-month low of $2.07 and a 12-month high of $15.00. The firm has a market capitalization of $2.68 billion, a PE ratio of -9.26 and a beta of 1.57.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.06. The firm had revenue of $7.00 million for the quarter, compared to analyst estimates of $4.34 million. As a group, research analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Barclays raised their price target on shares of Relay Therapeutics from $17.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday. Oppenheimer reaffirmed an "outperform" rating on shares of Relay Therapeutics in a report on Monday, March 16th. Guggenheim raised their price target on shares of Relay Therapeutics from $15.00 to $22.00 and gave the company a "buy" rating in a report on Friday, March 13th. Citizens Jmp raised their price target on shares of Relay Therapeutics from $15.00 to $17.00 and gave the company a "market outperform" rating in a report on Tuesday, March 17th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Relay Therapeutics in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $18.43.

Institutional Investors Weigh In On Relay Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RLAY. Caitong International Asset Management Co. Ltd bought a new stake in shares of Relay Therapeutics in the 4th quarter worth about $115,000. Seven Fleet Capital Management LP bought a new stake in shares of Relay Therapeutics in the 4th quarter worth about $618,000. Invesco Ltd. increased its position in shares of Relay Therapeutics by 139.6% in the 4th quarter. Invesco Ltd. now owns 865,481 shares of the company's stock worth $7,322,000 after purchasing an additional 504,291 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in shares of Relay Therapeutics in the 4th quarter worth about $106,000. Finally, XTX Topco Ltd bought a new stake in shares of Relay Therapeutics in the 4th quarter worth about $1,332,000. Institutional investors own 96.98% of the company's stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.